News Related to Complete Remission with Partial Hematologic Recovery

Related coverage linked through entity extraction aliases.

Moleculin says MIRACLE trial nears first unblinding with blinded CRc above 40%

May 13, 2026

Moleculin said its MIRACLE Phase 2B/3 AML trial is nearing first unblinding, with blinded CRc above 40% and CR around 30%. The first 45-subject readout is expected before June 30, 2026.

Moleculin Reports 40% Response Rate in Pivotal AML Trial, Unblinding Expected Q1 2026

Feb 18, 2026

Moleculin Biotech announced a preliminary blinded composite complete remission rate of 40% in the first 30 subjects of its Phase 2B/3 MIRACLE trial testing Annamycin plus cytarabine for relapsed or refractory acute myeloid leukemia.